Imatinib in melanoma: a selective treatment option based on KIT mutation status?

J Clin Oncol. 2007 Mar 1;25(7):e9. doi: 10.1200/JCO.2006.08.9664.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Mutation*
  • Piperazines / therapeutic use*
  • Proto-Oncogene Proteins c-kit / genetics*
  • Pyrimidines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit